Genmab AS (NASDAQ: GMAB) — Company Overview, News & Financial Data
Genmab AS focuses on transformative antibody therapies for cancer treatment, leveraging innovative technology.
Genmab AS
Genmab AS is an international biotechnology company focused on the discovery, development, and commercialization of therapeutic antibody products for cancer and other serious diseases. Headquartered in Copenhagen, Denmark, the company leverages proprietary technology platforms, including its DuoBody, HexaBody, DuoHexaBody, and HexElect technologies, to engineer targeted antibody therapies. Its portfolio includes multiple marketed products licensed to global pharmaceutical partners, generating royalty and milestone revenues, as well as proprietary and co-developed clinical candidates across hematologic and solid tumor indications. The company operates research, development, and commercial operations across Europe, North America, and Asia.
Snapshot
Operations
Products and/or services of Genmab AS
- Daratumumab Commercial Royalty Program: Human CD38-directed monoclonal antibody developed for subcutaneous and intravenous administration to treat multiple myeloma and light-chain amyloidosis. Licensed globally to Janssen Biotech, generating significant recurring royalty revenues from worldwide sales across multiple clinical indications.
- Epcoritamab Bispecific Cancer Therapy: Subcutaneously administered T-cell engaging bispecific antibody targeting CD3 and CD20 for treating relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Co-developed and co-commercialized globally with AbbVie across major pharmaceutical markets including North America, Europe, and Asia-Pacific.
- Ofatumumab Multiple Sclerosis Therapy: Human monoclonal antibody targeting CD20 approved for treating relapsing forms of multiple sclerosis in adult patients. Subcutaneously administered via self-injection pen and licensed worldwide to Novartis, returning percentage-based royalty revenues on net global commercial sales.
- Tisotumab Vedotin Antibody-Drug Conjugate: Antibody-drug conjugate directed against tissue factor expressed on solid tumors, approved for treating recurrent or metastatic cervical cancer with disease progression. Co-developed and co-promoted in partnership with Pfizer across the United States and designated global commercial territories.
- Bispecific Antibody Technology Platform: Proprietary antibody technology designed to create bispecific therapeutic candidates by enabling controlled fabrication of stable asymmetric IgG1 bispecific antibodies from two parental antibodies. Utilized internally and licensed to pharmaceutical partners to generate bispecific molecules targeting hematologic malignancies and solid tumors.
- Hexamerization Antibody Technology Platform: Proprietary technology platform engineered to enhance target-mediated effector functions of antibodies by promoting hexamerization upon cell surface binding. Applied across proprietary and partnered discovery programs to increase complement-dependent cytotoxicity against high-density target antigens on target tumor cell membranes.
Genmab AS executive team
- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO
- Mr. Anthony Pagano CPAExecutive VP & CFO
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer
- Mr. Christopher CozicExecutive VP & Chief People Officer
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director
- Mr. Takahiro HamataniSenior Director of Finance Japan & Non-Independent Director